Vaccines against meningococcal disease current and future technologies

Expert Opinion on Biological Therapy

Volumn 1, Issue 3, 2001, Pages 385-399

  Riddell, Anna ^a   Buttery, Jim ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Capsular s vitching; Conjugate vaccines; Correlate of protection; Genome sequencing; Hyporesponsiveness; Lipopolysaccharide; Neisseria meningitidis; Outer membrane proteins; Serum bactericidal activity

Indexed keywords

BACTERIAL ANTIGEN; DRUG CARRIER; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; PEPTIDE LIBRARY; VACCINE;

ADOLESCENT; ADULT; BACTERIAL MEMBRANE; CHILD; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOLOGY; INFANT; MENINGOCOCCOSIS; MICROBIOLOGY; NEISSERIA MENINGITIDIS; PRESCHOOL CHILD; REVIEW; VACCINATION;

ADOLESCENT; ADULT; ANTIGENS, BACTERIAL; BACTERIAL CAPSULES; BACTERIAL OUTER MEMBRANE PROTEINS; CHILD; CHILD, PRESCHOOL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMAN; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PEPTIDE LIBRARY; VACCINATION; VACCINES, CONJUGATE;

EID: 0035346799     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.3.385     Document Type: Article

References (87)

1. POOLMAN JT, VAN DER LAY PA, TOMMASSEN J Surface structures and secreted products of meningococci. In Meningococcal disease. Cartwright K (Ed.), John Wiley and sons Ltd. (1995)21-34.
2. FRASCH CE, WENDELL DZ, POOLMAN JT Serotype antigens of Neiserria meningiUdts and a proposed sccmc for designation of serotypes. Rev. Infect. Dis. (1985) 7504-10.
3. RAMSEY M, KACZMARSKI EB, RUSH M, MALLARD R, FARRINGTON P, WHITE J Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun. Dis. Rep. CDRRev. (1997) 7R55-R59.
4. SIM RJ, HARRISON MM, MOXON ER, TANG C Underestimation of meningococci in tonsilar tissue by nasopharyngeal swabbing, lancet (2000) 3561653-1654.
5. GOLDSCHNEIDER I, GOTSCHLICH EC, ARTENSTEIN MS Human immunity to the meningococcus.il. Development of natural immunity. J. Exp. Med. (1969) 1291327-1348.
6. GOLDSCHNEIDER I, GOTSCHLICH EC, ARTENSTEIN MS Human immunity to the meningococcus.I. The role of humoral antibodies./ Exp. Med. (1969)1291307-1326.
7. FIJEN CAP, BREDIUS ROM, KUIJPER EJ etal.Thc role of Fc receptor polymorphisms and C3 in the immune ' defence against Neisseria meningilidis in complement-deficient individuals. Clin. Exp. Immunol. (2000) 120338-334.
8. FEAVERS IM ABC of meningococcal diversity. Nature (2000) 404451.
9. TETTELIN H, SAUNDERS NJ, HEIDELBERG J et al. Complete genome sequence otNeisseria meningitidis serogroup B strain MC58. Science (.200O) 2871809-1815. • Important paper changing the way vaccine candidates will be identified.
10. PARKHILL J, ACHTMAN M, JAMES KD et a!. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature (2000) 404502-506. • Important paper changing the way vaccine candidates will be identified.
11. RIDING, CORKHILL Prophylactic vaccination in epidemic mcningococcal meningitis. / Hyg. (Camb) (1932) 32258.
12. GREENBERG, COOPER A somatic antigen vaccine for prevention of meningococcal cerebrospinal meningitis. Bull WHO (1965) 3321.
13. POLLARD AJ, GALASSINI, VAN DER VOORT EM et al Humoral immune responses to Neisseria meningitidis in children. Infect, Immun. (1999) 672441-2451. • Explores the reasons for poor response to candidate vaccines in infancy.
14. PLOTKIN SA Immunologie correlates of protection induced by vaccination. P/D/(2001) 2063-75-
15. PELTOLA H, MAKELA H, KAYHTY H et al Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N. Engl.J. Med. (1977) 297686-691.
16. GOLDSCHNEIDER I, LEPOW ML, GOTSCHLICH EC, MAUCK FT, BACHL F, RANDOLPH M Immunogenicity of group A and group C meningococcal poh/saccharides in human infants./ Infect. Dis. (1973) 128(6)769-776.
17. MILAGRES LG, LEMOS AP, MELES CE et al Antibody response after immunisation of Brazilian children with serogroup C meningococcal polysaccharide noncovalently complexed with outer membrane proteins. Braz.J. Med. Biol. Res. (1995) 28(9)981-989.
18. LEACH A, TWUMASI PA, KUMAH S et al Induction of immunologie memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine./ Infect. Dis. (1997) 175200-204.
19. MACLENNAN J, OBARO S, DEEKS J et al Immune response to revaccination with MACP in Gambian children following repeated immunisation during early childhood. Vaccine (1999) 173086-3093. • First evidence that prior immunisation with Men C polysaccharide vaccine does not prevent induction of immunologie memory with Men C conjugate vaccine.
20. GOLD R, LEPOW ML, GOLDSCHNEIDER I, DRAPER TF, GOTSCHLICH EC Kinetics of antibody production to Group A and Group C meningococcal polysaccharide vaccine administered during the first six years of life prospects for routine immunisation of infants and children. J1D (1979) 140690-697.
21. RICHMOND P, KACZMARSKI E, BORROW R et al Meningococcal C polysaccharide vaccine induces immunologie hyporesponsivcncss in adults that is overcome by meningococcal C conjugate vaccine. J. Infect. Dis. (2000) 181(2)76l-764.
22. MILLER MA, V7ENGER J, ROSENSTEIN N, PERKINS B Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa. PIDJ (1999) 18(12)1051-1059.
23. BUTTERY JP, MOXON ER Designing meningitis vaccines./ RCPLand. (2000) 34163-168.
24. RAJEWSKY K, SCHIRRMACHER V, NASE S, JERNE NK The requirement of more than one antigcnic determinant for immunogcnicity. J. Exp. Med. (1969) 129(6)1131-1143.
25. GRANOFF DM, HOLMES SJ, OSTERHOLM MT et al. Induction of immunologie memory in infants primed with haemophllus influenzae type b conjugate vaccines.J. Infect. Dis. (1993) 168663-671.
26. ANDERSON EL, BOWERS T, MINK CM et al. Safety and immunogcnicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect. Immun. (1994) 623391.
27. TWUMASI PA JR., KUMAH S, LEACH A et al A trial of a group A plus group C meningococcal polysaccharideprotein conjugate vaccine in African infants. / Infect. Dis. (1995) 171632-638.
28. FAIRLEY CK, BEGG N, BORROW R, FOX AJ, JONES DM, CARTWRIGHT K Conjugate meningococcal serogroup A and C vaccine rcactogcnicity and immunogcnicity in UK infants. JID (1996) 1741360.
29. LIEBERMAN JM, CHILI SS, WONG VK et al Safety and immunogcnicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial JAMA (1996) 2751499-1503.
30. MACDONALD NE, HALPERIN SA, LAW BJ, FORREST B, DANZIG LE, GRANOFF D Induction of immunological memory by conjugated vs. plain Men C PSV in toddlers. JAMA (1998) 2801685-1689.
31. RICHMOND P, BORROW R, MILLER E et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis. (1999) 179(6)1569-1572.
32. RICHMOND P, GOLDBLATT D, FUSCO PC et al. Safety and immunogenicityof a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine (1999) 18641-646.
33. MACLENNAN JM, SHACKLEY F, HEATH P et al Safety, immunogenicity and induction of immunological memory by a serogroup C meningococcal vaccine in infants. JAMA (2000) 2832795.
34. ENGLISH M, MACLENNAN, JM, BOWEN-MORRIS JM et al. A randomised, double-blind, controlled trial of the immunogcnicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine (2001) 191232-1238.
35. ANONYMOUS Enhanced surveillance of suspected meningococcal disease. CDft Weekly (2000) 978-79.
36. ANONYMOUS Menlngococcal disease falls in vaccine recipients. CDR Weekly (2000) 10133-136.
37. ANONYMOUS Safety of meningitis vaccine. CDR Weekly (2000) 10213-216.
38. ANONYMOUS Safety of group C meningococcal vaccine. CDR Weekly (.2000) 10311-314.
39. BARBOUR ML, BOOY R, CROOK D\V et al. Hib carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine. P7D/(1993) 12478-84.
40. DIMARTINO M, CALI G, ASTORRE P, USAI GC, FERRARI R, STROFFOLINI T Meningococcal carriage and vaccination in army recruits in Italy. Bollettino dell Istittito Sieroterapico Milanese (1990) 69(0357-359.
41. PELTOLA H, KAYHTY H, SIVONEN A, MAKELA H Hib capsular polysaccharidc vaccine in children a double-blind field study of 100000 vaccinées 3 months to 5 years of age in Finland. PediatricsdyTT) 60730-737.
42. ZHANG Q, CHOO J, EVERARD J, JENNINGS R, FINN A Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharidc vaccines in adolescents. Infect. Immun. (2000) 682692-2697.
43. GHEESL1NG LL, CARLONE GM, PAIS 13 et al Multicenter comparison of Neisseria meningitidis serogroup C anticapsular polysaccharidc antibody levels measured by a standardized enzyme-linked bnmunosorbcnt assay./ Clin. Microbiol. (1994) 321475-1482.
44. GRANOFF DM, MASLANKA SE, CARLONE GM et al. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharidc that correlate with bactericidal responses. Clin. Diag. Lab. Immunol. (1998) 5479-485.
45. BORROW R, ANDREWS N, GOLDBLATT D, MILLER E Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom réévaluation of correlates of protection. Infect. Immun. (2001) 69(3)1568-1573.
46. MASLANKA SE, GHEESLING LL, LIBUTTI DE et al Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. atn. Diag. Lab. Immunol. (1997) 4156-167.
47. GRANOFF DM, MASLANKA SE, CARLONE GM et al A modified enzyme-linked immunosorbant assay for measurement of antibody responses to meningococcal C poh/saccharide that correlate with bactericidal responses. Clin. Diag. Lab. Immunol. (1998) 5(4)479-485.
48. MASLANKA SE. TAPPERO JW. PLIKAYTIS BD et al Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titres in sera from young children from Montana immunized with a licensed polysaccharidc vaccine. Infect. Immun. (1998) 662453-2459-
49. LEHMAN AK, HALSTENSEN A, HOLST J, BASSOE CF Functional assays for evaluation of serogroup B mcningococcal structures as mediators of human opsonophagocytosis.J. 1mm. Methods (1997) 20055-68.
50. POLLARD AJ, GALASSINI R, ROUPPE VAN DER VOORT EM et al. Cellular immune response to Nelsseria tneningttidis in children. Infect. Immun. (1999) 672452-2463. • Examines age-dependent defects in immunity which may impact on the response to OMP vaccines.
51. ISON CA, ANWAR N, COLE MJ et al Assessment of immune response to mcningococcal disease comparison of a whole-blood assay and the serum bactericidal assay. Microbial Pathogenesis (1999) 27207-214.
52. QUAKYI EK, FRASCH CE, BULLER N, TSAI C-M Immunisation with mcningococcal outer membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitides infection and septic shock. JID (1999) 180747-754.
53. TOROPAINEN M, KAYHTY H, SAARINEN L et al The infant rat model adapted to evaluate human sera for protective immunity to group B meningococcus. Vaccine (1999) 172677.
54. SWARTLEYJS, MARFIN AA, EDUPUGANTIS étal. Capsule switching of Neisseria meningitides. PNAS (1997) 94271.
55. DAGAN R, ESKOLA J, LECLERC C, LEROY O Reduced response to multiple vaccines sharing common protein cpitopcs that arc administered simultaneously to infants. Infect. Immun. (1998) 662093-2098.
56. FUKASAWA LO, GORLA MCO, SCHENKMAN RPF et al. Neisseria meningitides scrogroup C polysaccharide and serogroup B OMV conjugate as a bivalent meningococcus vaccine candidate. Vaccine (1999) 172951-2958.
57. GRANOFF DM, GUPTA RK, BELSHE RB, ANDERSON EL Induction of immunologie refractoriness in adults by Meningococcal C polysaccharide vaccination. JID (1998) 178870-874.
58. RAJANDREAM MA. RUTHERFORD KM. SIMMONDS M et al. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature (2000) 404502-506.
59. PIZZA M, SCARLATO V, MASIGNANI V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (2000) 2871816-1820. •• Landmark paper describing the use of genomic sequencing to identify surface exposed proteins for use as vaccine candidates for group B meningococcus.
60. SUN YH, BAKSHI S, CHALMERS R, TANG C Functional genomics of Neisseria meningitidis pathogcnesis. Nature Med. (2000) 61269-1273. • Analysis of insertional mutants of N. meningitidis to understand the pathogenesis of bacteraemia in meningococcal disease.
61. GROTHAUS MC, SRIVASTAVA N, SMITHSON L et al.-. Selection of an immunogenic peptide mimic of the capsular polysaccharide of TV. meningitides serogroup A using a peptide display library. Vaccine (2000) 181253. • Novel approach to vaccine design using a phage library to identify a peptide mimic of the group A capsular polysaccharide.
62. CHARALAMBOS BM, FEAVERS IM Peptide mimics elicit antibody responses against the outer membrane lipooligosaccharide of groupB Neisséria meningltides. PEAKMicrobiol Lett. (2000)19145-50.
63. FRASCH CE, COETZEE GJ, WU L, ROSENQVIST E Immune responses of adults and children to scrogroup B Neisseria meningitises outer membrane protein vaccines. In Bacterial vaccines. RobbinsJB (Ed.), Praeger (1987)262-272.
64. SIERRA GV, CAMPA HC, VARCACEL NM Vaccine against group B Neisseria meningitides protection trial and mass vaccination results in Cuba. NIPH Ann. (1991) 14195-207.
65. BJUNE G. HOIBY EA. GRONNESBY JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet (1991) 3381093-1096.
66. DE MORAESJC, PERKINS BA, CAMARGO MC étal. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet (1992) 3401074-1078.
67. BOSLEGO J, GARCIA J, CRUZ C Efficacy, safety and immunogcnicity of a meningococcal group B (15P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine (1995) 13821-829.
68. NORONHA CP, STRUCHINER CJ, HALLORAN ME Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil a case-control study. IntJ. Epidermiol. (1995) 241050-1057.
69. PEETERS CC, RUMKE HC, SUNDERMANN LC Phase 1 clinical trial with a hexavalent Por A containing meningococcal outer membrane vesicle vaccine. Vaccine (1996) 141009-1015.
70. PERKINS BA, JONSDOTTIR K, BRIEM H et al Immunogcnicity of two efficacious outer membrane proteinbased serogroup B meningococcal vaccines among young adults in Iceland. / Infect. Dis. (1998) 177683-691.
71. MIIAGRES LG, CECILIA AG, SACCHI CT, RODRIGUES MM Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunisation with an outer membrane vaccine. Infect. Immun. (1998) 664755-4761.
72. TAPPERO JW, LAGOS R, BALLESTEROS AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines a randomized controlled trial in Chile. JAMA (1999) 2811520-1527.
73. DE KLEIN ED, DE GROOT R, LABADIE J et al Immunogenicity and safety of a hexavalent meningococcal OMV vaccine in children of 2-3 and 7-8 years of age. Vaccine (2000) 181456.
74. CARTWRIGHT K. MORRIS R. RUMKE H et al Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine (1999) 172612-2619-• First large scale UK trial of an OMP vaccine for group B meningococcus.
75. CARBONARE SB, ARSLANIAN C, SILVA M, FARHAT CK, CARNEIRO-SAMPAIO MMS The antimeningococcal vaccine VAMENGOC B-C Induced poor serum and salivery antibody response in young Brazilian children. /VU/C1995) 14797-803.
76. LISSOLO L, MAITRE-W1LMOTTE C, DUMAS P étal.-. Evaluation of transferring binding protein 2 within the transferring binding complex as a potential antigen for future mcningococcal vaccines. Infect. Immun. (1995) 63884-890.
77. ALA'ALDEEN DAA, STEVENSEN P, GRIFFITHS E Immune responses in humans and animals to meningococcal binding proteins implications for vaccine design. Infect. Immun. (1994) 622984.
78. ALA'ALDEEN DAA Transferrin receptors of Neisseria meningitidis promising candidates for a broadly cross-protective vaccine. J. Med. Micro. (1996) 44237-243.
79. GOMEZ JA, HERNANDEZ E, CRIADO MT, FERREIROS CM Effect of adjuvants in the isotypes and bactericidal activity of antibodies against transferring-binding proteins of Nelsseria meniiigllidis. Vaccine (1998) 171633-1639.
80. SAUKKONEN K, LEINONEN M, ABDILLAHI H, POOLMAN JT Comparative evaluation of potential components for group B mcningococcal vaccine bypassivc protection in the infant rat and in vitro bactericidal assay. Vaccine (1989) 7325-328.
81. ANDERSEN SR, BJUNE G, LYNGBY J, BRYN K, JANTZEN E Short-chain lipopotysaccharide mutants of serogroup B Neisseria meningitises of potential value for production of outer membrane vesicle vaccines. Microb.patbog.(\y)5) 19159-160.
82. ANDERSEN SR, KOLBERG J, HOIBY A et al. lipopolysaccharide heterogeneity and escape mechanisms of Neisserta meningitides possible consequences for vaccine development. Microb. Pathog. (1997) 23139-155.
83. PLESTEDJS, MAKEPEACE K, JENNINGSMP etal. Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis. Infect. Immun. (1999) 675417-5426. • Immunogens capable of eliciting functional antibodies specific to inner core structures were identified as possible vaccine candidates for serogroup B disease.
84. MOXON ER, HOOD D, RICHARDS J Bacterial lipopolysaccharides candidate vaccines to prevent A', meningitides and H. influenzas infections. Adv. Exp. Med. Bio!. (1998) 435237-243.
85. TANG C, MOXON R, LEVINE MM For discussion live attenuated vaccines for group B meningococcus. Vaccine (1999) 17114-117.
86. OFTUNG F, NAESS LM, WETZLER LM et al. Antigenspecific T-cell responses in humans after intranasal immunization with a mcningococcal serogroup B outer membrane vesicle vaccine. Infect. Immun. (1999) 67921-927.
87. MUNOZ FM, ENGLUND JA A step ahead infant protection through maternal immunisation. Fed. Clin. North Am. (2000) 47449.